You're asking about a compound with a rather complex chemical name: **1-(phenylmethyl)-4-(phenylmethylthio)pyrazolo[3,4-d]pyrimidine**. While I don't have access to specific research data on this compound, I can break down its structure and explain why compounds with similar structures are often of interest in research:
**Understanding the Structure:**
* **Pyrazolo[3,4-d]pyrimidine:** This part of the name refers to a fused ring system. It's a core structure commonly found in many drugs and biologically active molecules.
* **1-(phenylmethyl)-:** This indicates a benzyl group (a phenyl ring attached to a CH2 group) is attached at the 1 position of the pyrazolo[3,4-d]pyrimidine ring.
* **4-(phenylmethylthio)-:** This indicates another benzyl group, but this time it's linked through a sulfur atom (thio) at the 4 position of the pyrazolo[3,4-d]pyrimidine ring.
**Why this type of structure might be of interest in research:**
* **Potential for Drug Development:** Compounds with similar structures to 1-(phenylmethyl)-4-(phenylmethylthio)pyrazolo[3,4-d]pyrimidine are often investigated as potential drugs.
* **Targeting Specific Enzymes:** Pyrazolo[3,4-d]pyrimidine derivatives have shown activity against a range of enzymes, including kinases, which play crucial roles in cellular signaling.
* **Biological Activity:** The benzyl groups on this molecule might contribute to its ability to bind to biological targets, making it more selective and potent.
* **Chemical Exploration:** Even if this specific compound isn't directly linked to a known drug, it could be of interest to researchers for several reasons:
* **Studying Structure-Activity Relationships (SAR):** By comparing the activity of this compound to other structurally similar pyrazolo[3,4-d]pyrimidine derivatives, scientists can learn how different substituents affect biological activity. This helps them design better drugs.
* **Synthesizing New Compounds:** This compound might serve as a starting point for creating other novel molecules with potentially interesting biological properties.
**To find more information, you'll likely need to:**
* **Search chemical databases:** Databases like PubChem, SciFinder, or Reaxys can provide information about the compound's properties, known syntheses, and any published research.
* **Consult scientific literature:** Searching for publications related to pyrazolo[3,4-d]pyrimidine derivatives or related chemical classes may reveal information about the compound or similar structures.
* **Contact researchers specializing in medicinal chemistry or drug discovery:** They might be able to provide more specific insights into the potential significance of this compound.
Remember, without specific research data, it's impossible to say with certainty why 1-(phenylmethyl)-4-(phenylmethylthio)pyrazolo[3,4-d]pyrimidine might be important. However, its structure suggests it could be a promising candidate for further investigation in the field of medicinal chemistry.
ID Source | ID |
---|---|
PubMed CID | 3842823 |
CHEMBL ID | 245962 |
CHEBI ID | 115723 |
Synonym |
---|
STL349058 |
1-benzyl-4-(benzylsulfanyl)-1h-pyrazolo[3,4-d]pyrimidine |
smr000148620 |
MLS000557904 |
1-benzyl-4-benzylsulfanyl-1h-pyrazolo[3,4-d]pyrimidine |
1-benzyl-4-benzylthio-1h-pyrazolo[3,4-d]pyrimidine |
1-benzyl-4-benzylsulfanyl-pyrazolo[3,4-d]pyrimidine |
CHEBI:115723 |
CHEMBL245962 |
1-benzyl-4-benzylsulfanylpyrazolo[3,4-d]pyrimidine |
HMS2410P04 |
AKOS022095920 |
Q27198074 |
1-(phenylmethyl)-4-(phenylmethylthio)pyrazolo[3,4-d]pyrimidine |
Class | Description |
---|---|
pyrazolopyrimidine | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 50.1187 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 25.1189 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
TDP1 protein | Homo sapiens (human) | Potency | 29.0929 | 0.0008 | 11.3822 | 44.6684 | AID686978 |
apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 28.1838 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 19.9526 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 25.1189 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 25.1189 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 31.6228 | 0.0018 | 15.6638 | 39.8107 | AID894 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 79.4328 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 32.6427 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
pyruvate kinase PKM isoform a | Homo sapiens (human) | Potency | 5.0119 | 0.0401 | 7.4590 | 31.6228 | AID1631; AID1634 |
survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 3.5481 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
lamin isoform A-delta10 | Homo sapiens (human) | Potency | 19.9526 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
Inositol monophosphatase 1 | Rattus norvegicus (Norway rat) | Potency | 1.0000 | 1.0000 | 10.4756 | 28.1838 | AID1457 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID306130 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv | 2007 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6 | New thiopyrazolo[3,4-d]pyrimidine derivatives as anti-mycobacterial agents. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (33.33) | 29.6817 |
2010's | 3 (50.00) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.41) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |